Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a late stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.

The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  The company is rapidly advancing peginterferon lambda, a first-in-class interferon, toward registration for the treatment of HDV.  Eiger has initiated a rolling NDA submission for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to complete NDA submission and MAA submission in the first quarter of 2020.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger BioPharmaceuticals Closes Merger With Celladon
Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs PALO ALTO, Calif. , March 22, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. ( NASD : EIGR) today announced completion of its merger with Celladon Corporation
Toggle Summary Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
PALO ALTO, Calif., March 28, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product status to ubenimex for the treatment of pulmonary arterial hypertension (PAH).
Toggle Summary Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Meeting
PALO ALTO, Calif. , March 30, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc, (NASDAQ:  EIGR) today announced that abstracts from its Hepatitis Delta Virus (HDV) development program will be presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain ,
Toggle Summary Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. "Chuck" Bramlage
PALO ALTO, Calif. , April 4, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc , (NASDAQ:  EIGR) announced today that its Board of Directors has appointed Charles J. "Chuck" Bramlage as a member of the Board. Mr. Bramlage is a pharmaceutical industry veteran with extensive experience in marketing,
Upcoming EventsMore >>
More events are coming soon.
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.